Zhiyuan Robot

This snapshot intentionally separates public proof from unresolved private metrics; null means unsupported in reviewed public evidence.

Coverage is partial and limited to leaders publicly named by the company or cited in reviewed independent coverage.

This is a public stakeholder map, not a cap table. Economic rights, board control, and secondary liquidity remain undisclosed.

This chronology is the chapter's single timeline of record and includes both positive scale events and adverse legal signals visible in public sources.

Boundary logic distinguishes the company's real public product footprint from overbroad robotics TAM definitions.

This table intentionally mixes top-down and commercialization lenses; null marks a company-specific denominator that public evidence does not yet support.

Representative buyer map only; buyer, user, and payer roles vary materially by geography and use case.

Timing matters as much as direction; several “drivers” only help if product reliability and deployment economics improve in parallel.

Selected set covers the most visible direct peers and leaves out many smaller entrants or non-humanoid substitutes.

Cells summarize reviewed public evidence only; low visibility does not prove low capability.

Public price disclosure remains poor across the peer set, so packaging and deployment proof matter more than list-price comparison.

The register focuses on moat durability rather than general company risk; many threats arise from success-strain, not only from obvious failure.

Public evidence supports the existence of each stream, but not the revenue mix or recognition schedule for any one stream.

Pricing evidence mixes different products, scenarios, and contract structures; it should be read as boundary-setting rather than as a clean price book.

The table mixes direct Zhiyuan evidence with public peer benchmarks because Zhiyuan does not disclose a full unit-economics pack.

Capital adequacy remains the least transparent part of the Zhiyuan underwriting case in public sources.

These are not nice-to-have metrics; they are the minimum package required for real underwriting in a capital-intensive hardware business.

Matrix covers the major public product and platform surfaces visible in reviewed sources, not every internal program or accessory.

Benefits are phrased as plausible workflow outcomes from reviewed sources, not as audited customer KPIs.

Architecture is reconstructed from public technical and deployment evidence, not from an internal engineering diagram.

The most important trust rows are still null-like because the reviewed public record does not provide a complete control pack.

The roadmap is reconstructed from public releases and may omit internal priorities or cancelled programs.

Segments are grouped by how value is bought and deployed, not only by NAICS-style industry labels.

Trajectory rows mix live deployment, order expansion, procurement, and partner-commercialization signals; each should be weighed differently.

Named proof is directionally strong for a young humanoid startup, but still narrower than a mature enterprise robotics vendor’s customer ledger.

The table intentionally separates true retention metrics from weaker but still useful public proxies.

Risks are framed from a customer-portfolio angle rather than from general company operations.

This register emphasizes external compliance and legal exposure rather than pure product bugs.

Most critical operational metrics are private, so the table distinguishes observed risks from missing controls.

Dependency risk is commercial as much as technical: the weakest node can slow the whole rollout engine.

People and execution risks combine org design, commercialization process, and finance discipline.

Kill criteria are intentionally evidence-based rather than narrative-based.

The anti-thesis is not theoretical; it flows directly from what public sources still do not disclose.

This summary intentionally separates attractiveness of the company from attractiveness of the current public valuation context.

Ranges are analytical estimates, not market facts; they are meant to bracket underwriting outcomes given public evidence.

Comps are intentionally heterogeneous; the point is contextual triangulation, not a false-precision average multiple.

These triggers define when a promising story should stop receiving benefit-of-the-doubt valuation treatment.

These are the minimum diligence asks most likely to change the investment decision, not an exhaustive list.